Tacrolimus, which is also known as FK506, is a fairly new drug that is considered by many experts to be as effective as cyclosporine. An alternative drug choice for patients that cannot tolerate cyclosporine, tacrolimus has been the subject of much research in recent years. Used to treat rej...
Twitter Google Share on Facebook rabbit (redirected fromantithymocyte globulin) Thesaurus Medical Financial Encyclopedia rab·bit (răb′ĭt) n.pl.rab·bitsorrabbit 1.Any of various long-eared, short-tailed, burrowing mammals of the family Leporidae, such as the commonly domesticated speciesOrycto...
3. Anti-Rejection Strategies and Clinical Outcomes 3.1. Introduction To prevent xenogeneic rejection, three strategies have been used, namely, anti-rejection drugs, encapsulation, and Sertoli cells. All strategies have shown positive outcomes; however, further improvement is desirable. ...
inhibiting squalene-synthase and this may be of interest in the context ofergosterolbiosynthesis in the fungal cell[97]. Thenatural producttacrolimus, currently used as animmunosuppressive agentin various indications ranging from the prevention ofrenal transplant rejectiontopsoriasis vulgaris, binds to an...
Drug-Drug Interaction Between Tacrolimus and Azole Anti-Fungal Agents, Itraconazole and Voriconazole, in Allogeneic Hematopoietic Stem Cell Transplantation RecipientsTransplantationcytomegalovirusprophylaxisvalganciclovirAmpullary and proximal pancreatic duct strictures are well known to result in recurrent episodes of...
Analogous to rapamycin, tacrolimus (also known as TAC or FK506) demonstrates similar efficacy when incorporated with nanomaterials for treating ocular inflammation. Wu et al. devised TAC-loaded methoxy poly (ethylene glycol-block-poly (d, l)-lactic-co-glycolic acid) nanoparticles (TAC-NPs) using...
Tacrolimus, a calcineurin inhibitor and first-line immunosuppressive drug, prevents organ and tissue rejection following transplantation [32,33,34] and promotes long-term safety and efficacy against myasthenia gravis [35] and neuromyelitis optica spectrum disorder [36]. Additionally, few reports have des...
These treatments eradicate the underlying disease and suppresses and eradicate the host immune system which allow donor stem cells to home into the bone marrow without the risk of graft rejection. The administration of myeloablative or reduced-intensity or non-myeloablative treatments may be used to ...
5. The method of claim 1 further comprising administering a non-biological disease modifying anti-rheumatic drug (DMARD) to the patient during the treatment. 6. 6.-23. (canceled) 24. A method of treating giant cell arteritis (GCA) in a patient comprising subcutaneously administering an IL-...
Skip to main contentSkip to article